Anticoagulation in a Patient with Atrial Fibrillation and Recurrent Falls
A 78-year-old woman with permanent atrial fibrillation, hypertension, and stage 3 chronic kidney disease (baseline creatinine 1.6 mg/dL, estimated CrCl 32 mL/min) presents after her third mechanical fall in six months; the most recent fall caused a left wrist fracture but no head trauma. Her CHA2DS2-VASc score is 5 (age, hypertension, female sex, plus prior TIA two years ago) and HAS-BLED is 3 (hypertension, renal function, age >65). She lives alone, uses a walker inconsistently, and takes amlodipine, metoprolol, and atorvastatin. She is adamant she 'does not want a stroke' but her daughter is frightened by the falls. Current medications include no anticoagulant because a prior clinician stopped warfarin after the second fall.
1. How should you frame the decision about restarting anticoagulation, and what does the evidence say about falls as a reason to withhold it?
Read the worked answer
Falls are a weak and frequently overstated contraindication. Modeling studies suggest a patient would need to fall on the order of hundreds of times per year before the hemorrhage risk of anticoagulation outweighed its stroke-reduction benefit; three falls in six months does not approach that threshold. With a CHA2DS2-VASc of 5, her annual stroke risk is high (roughly 6–7% per year untreated), and her prior TIA marks her as especially high risk. The conversation should acknowledge the daughter's fear, quantify both risks in plain language, and explain that the goal is to reduce the chance of a devastating stroke while simultaneously addressing fall risk. Withholding anticoagulation is not a neutral choice-it is an active decision to accept a substantial stroke risk. Document a shared decision that favors anticoagulation plus a fall-prevention plan.
2. Which anticoagulant would you choose given her renal function, and what dosing and monitoring considerations apply?
Read the worked answer
Options include dose-adjusted warfarin (target INR 2–3) or a direct oral anticoagulant with renal dose adjustment. Among DOACs, apixaban has the most favorable bleeding profile and can be used at 2.5 mg twice daily if two of three criteria are met (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL)-she meets age and creatinine, so reduced dosing is appropriate if weight is not a factor; verify weight before finalizing. Rivaroxaban and dabigatran require more caution at CrCl 30–50. Warfarin remains reasonable if adherence or cost is a concern and INR monitoring is feasible. Whichever is chosen, pair it with: deprescribing or reviewing fall-risk medications, a physical therapy/balance referral, home safety evaluation, blood pressure optimization to reduce orthostatic falls, and periodic renal function reassessment (at least annually, more often if CKD progresses).
3. What else must be addressed to make anticoagulation safe in this patient?
Read the worked answer
Anticoagulation alone is insufficient; the falls themselves are the modifiable problem. Assess for orthostatic hypotension (amlodipine and volume status), review sedating or hypotension-inducing agents, evaluate gait and vision, address home hazards, and consider vitamin D and bone health given her fracture. A fall-risk multifactorial assessment is the standard of care. Also confirm no contraindication such as active bleeding, and plan for patient education on signs of bleeding and when to seek care. The key judgment is that the presence of falls should trigger a comprehensive fall-prevention effort, not abandonment of stroke prophylaxis.